Allergan Inc. (AGN) reported that its third-quarter net earnings attributable to stockholder were $179.0 million or $0.58 per share, compared to $165.4 million or $0.54 per share in the year ago quarter.
Non-GAAP earnings share attributable to stockholders were $215.4 million or $0.70, compared to $200.4 million or $0.65 per share in the third quarter of 2008. Analysts polled by Thomson Reuters expected the company to report earnings of $0.70 per share for the quarter. Analysts' estimates typically exclude special items.
Revenues for the quarter were $1.14 billion, compared to $1.10 billion in the prior year quarter. Sixteen analysts had consensus revenue estimate of $1.08 billion for the quarter.
Allergan also announced that its Board has declared a third quarter dividend of $0.05 per share, payable on November 30, 2009 to stockholders of record on November 9, 2009.
For the fourth quarter of 2009, Allergan expects total product net sales to be between $1.110 billion and $1.160 billion. Non-GAAP earnings per share attributable to stockholders are expected to be between $0.75 and $0.77. Analysts expect the company to report earnings of $0.75 per share on revenues of $1.10 billion for the fourth-quarter.
The company raised its fiscal 2009 non-GAAP earnings attributable to stockholders guidance to a range of $2.75 - $2.77 per share, from the prior outlook of $2.71 - $2.75 per share. For the full year of 2009, Allergan now expects total product net sales to be between $4.350 billion and $4.400 billion, compared to prior range of $4.2 billion- $4.3 billion.
Analysts expect the company to report earnings of $2.75 per share on revenues of $4.32 billion for fiscal 2009.
For comments and feedback: editorial@rttnews.com